Stocktoria
Niagen Bioscience, Inc. NAGE
Nasdaq · XNAS · stock · Medicinal Chemicals & Botanical Products · website · IPO 2007-06-25
Niagen Bioscience, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $129.4M | $99.6M | $83.6M | $72.0M | $67.4M |
| Gross profit | $83.2M | $61.6M | $50.8M | $42.8M | $41.5M |
| R&D expense | $6.3M | $6.0M | $5.0M | $4.8M | $3.8M |
| Operating income | $16.3M | $7.7M | -$5.6M | -$18.6M | -$27.1M |
| Interest expense | — | — | — | — | $55,000 |
| Income tax | $810,000 | $305,000 | $0 | — | — |
| Net income | $17.4M | $8.6M | -$4.9M | -$16.5M | -$27.1M |
| EPS (diluted) | $0.20 | $0.11 | $-0.07 | $-0.24 | $-0.40 |
| Operating cash flow | $13.5M | $12.1M | $7.1M | -$15.1M | -$24.2M |
| Cash & equivalents | — | $44.5M | $27.2M | $20.3M | $28.2M |
| Inventory | $20.4M | $9.2M | $14.5M | $14.7M | $13.6M |
| Total assets | $106.4M | $68.3M | $55.0M | $54.1M | $57.8M |
| Total liabilities | $29.9M | $22.2M | $26.5M | $25.4M | $26.1M |
| Shareholders' equity | $76.5M | $46.1M | $28.5M | $28.7M | $31.7M |
Source: SEC EDGAR filings · CIK 0001386570 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.